Please login to the form below

Not currently logged in
Email:
Password:

New Accounts, May, 2009, Advertising

New pharmaceutical account wins notified to us by the winning agency for the period March 2009 and April 2009 inclusive:

New pharmaceutical account wins notified to us by the winning agency for the period March 2009 and April 2009 inclusive:

       

CLIENT

PRODUCT

THERAPEUTIC AREA

WINNING AGENCY

ApaTech Actifuse Bone graft material Fleishman-Hillard International
Bausch & Lomb
Ocuvite
Ophthalmology
Pulsar Healthcare Communications
Bausch & Lomb
PreserVision
Ophthalmology Pulsar Healthcare Communications
Bupa Home Healthcare
N/A
Corporate
Pulsar Healthcare Communications
CarieScan
CarieScan
Dentistry
Pulsar Healthcare Communications
IS Pharma
Haemopressin/ Variquel (Europe)
Hepatology
Pulsar Healthcare Communications
NHS PCT strategy
World class commissioning
Hive
Pfizer Europe
Celebrex Arthritis MSA Market Media
Pfizer Europe
Aricept Alzheimer's disease MSA Market Media
Reckitt Benckiser         
Nurofen for Children
Analgesia
Hive
Roche        
Bonviva
Osteoporosis
MSA Market Media
Spectrum Thea
Virgan
Ophthalmology
Pulsar Healthcare Communications
Teva Ireland
Naramerg
CNS
Pulsar Healthcare Communications
TEVA         
Spotlight Range
Various therapy areas MSA Market Media
TEVA           
QVAR Respiratory MSA Market Media

  

Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may not be involved with some of the products listed in other ways, or in domestic, overseas or international markets.

To submit an entry for New Accounts, email new_accounts@pmlive.com

8th June 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics